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Abstract 
Background and Objective: Mycobacterium tuberculosis has been proposed as a 
candidate agent for the cause of sarcoidosis.  The QuantiFERON-TB Gold test has a 
higher specificity for detecting Mycobacterium tuberculosis infection than the 
conventional tuberculin skin test.  This study aimed to investigate the rate of positive 
QuantiFERON-TB Gold results in Japanese sarcoidosis patients. 
Patients and Methods: The QuantiFERON-TB Gold test, an enzyme-linked 
immunosorbent assay, was used to assess the levels of interferon-gamma resulting from 
immune responses to Mycobacterium tuberculosis-specific antigens, namely early 
secretory antigen target 6 and culture filtrate protein 10, in 90 Japanese sarcoidosis 
patients. 
Results: The QuantiFERON-TB Gold result was positive in 3 of the 90 patients tested. 
Conclusion: The positivity rate of QuantiFERON-TB Gold was 3.3% in Japanese 
sarcoidosis patients. 
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Introduction 
The QuantiFERON-TB Gold (QFT) test, a whole blood interferon-gamma 
assay, is a new technique for diagnosing Mycobacterium tuberculosis infection (TBI) 
(1,2).  Although the tuberculin skin test (TST) is the current standard diagnostic test 
for detecting latent TBI, it shows low specificity.  This probably arises because its 
purified protein derivative (PPD) is a mixture of mycobacterium antigens that are also 
present in both bacillus Calmette-Guérin (BCG) strains and non-tuberculous 
mycobacteria (NTM).  Since the antigens in the QFT are early secretory antigen target 
6 (ESAT-6) and culture filtrate protein 10 (CFP-10), which are specific to M. 
tuberculosis and absent from BCG vaccine strains and the majority of NTM species, the 
QFT can detect latent TBI with higher specificity than the conventional TST (3,4). 
Sarcoidosis is a systemic granulomatous disorder of unknown etiology (5).  
Due to the clinical and pathological similarities, mycobacterial infections, especially 
TBI, have been proposed as candidates for infectious causes of sarcoidosis.  However, 
it remains controversial whether sarcoidosis is caused by M. tuberculosis, since 
numerous studies using currently available molecular techniques have resulted in 
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positive or negative results (5,6).  Furthermore, it is sometimes difficult in practice to 
distinguish between sarcoidosis and TBI (5).  The TST is unsuitable for detecting TBI 
in sarcoidosis patients due to its anergically-depressed reaction.  Burton used 
interferon-gamma production by alveolar lymphocytes in response to tuberculosis PPD 
stimulation to distinguish sarcoidosis from TBI (7). 
Recently, Drake et al. reported that one ESAT-6 peptide was recognized in 8 
of 26 sarcoidosis patients using an enzyme-linked immunospot (ELISPOT) assay (8).  
The present study aimed to elucidate the rate of positive QFT results in Japanese 
sarcoidosis patients. 
 
Methods 
Patients and controls  
Ninety consecutive patients with sarcoidosis (29 males, 61 females; mean age: 
48.7 yr) were included in this study.  The diagnosis of sarcoidosis was based on a 
compatible clinical picture and histological finding of noncaseating granulomas (5).  
Cases were excluded if they had previously been diagnosed with TBI or had chest 
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radiographic evidence of healed TBI.  None of the patients was under systemic steroid 
or immunosuppressive therapy.  Our Institutional Review Board approved the study 
protocol and each patient gave written informed consent. 
 
Sample Collection and TST 
A heparinized peripheral blood sample was collected from each patient.  For 
the TST, 0.1 ml of tuberculin PPD (equivalent to 3 tuberculin units of PPD-S; Nippon 
BCG Manufacturing, Tokyo, Japan) was injected intradermally and the induration 
diameter was measured after 48-72 h. 
 
Whole Blood Interferon-gamma Assay 
Interferon-gamma production in whole blood was measured using the QFT, a 
commercially available enzyme-linked immunosorbent assay (ELISA) kit (Cellestis, 
Carnegie, Australia).  The assay was performed by a blinded investigator according to 
the manufacturer’s instructions.  We interpreted the test result as positive if the 
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concentration of interferon-gamma for either of the antigens was more than 0.35 IU/ml 
(4,9). 
 
Results 
All 90 patients had sarcoid lesions in their lungs.  TST results were available 
in 84 patients, among which 2 and 1 patients showed indurations of >10 and 15 mm, 
respectively.  The QFT was performed in all 90 patients, and their levels of 
interferon-gamma response to phytohemagglutinin were at least 0.5 IU/ml.  All 
individual tests were deemed valid.  Among the 90 sarcoidosis patients, the QFT result 
was positive in 3 patients (3.3%; Table 1).  Their specimens were negative for M. 
tuberculosis by acid fast staining, culture and PCR evaluation of lung or skin tissues.  
During a 1-year follow-up, none of the patients developed TBI.  There were no 
characteristic clinical, radiographic or pathologic differences between the 3 
QFT-positive patients and 87 QFT-negative patients. 
 
Discussion 
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In the present study, 3 of 90 sarcoidosis patients showed a positive QFT result.  
They had no evidence of TBI in microbiological, radiological and pathological 
examinations.  The QFT positivity rate in our Japanese sarcoidosis patients was 3.3%, 
which was nearly identical to those in healthy non-sarcoidosis subjects (3,4,9-12). 
 Although there is no definitive method for diagnosing latent TBI, many 
studies have evaluated the specificity of the QFT in low-risk subjects.  Some surveys 
mainly targeted students, while others contained middle-aged subjects with no identified 
risks for M. tuberculosis exposure (3,4,9-12).  In a Japanese survey, the specificity of 
the QFT for a BCG-vaccinated group was reported to be 98.1% (4).  Another Japanese 
investigation showed that 94% of healthy volunteers were negative for the QFT (9).  
Currently, the high specificity of the QFT is recognized independently of BCG 
vaccination status and age in low-risk groups (3,4,9-12).  In the present study, 3 
patients showed a positive QFT response (3.3%).  Compared with previous data 
targeting various TB-prevalent countries and study populations (3,4,9-13), the rate of 
positive results was almost identical to those in non-sarcoidosis subjects. 
In this study, we cannot provide a link between Japanese sarcoidosis patients 
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and TBI detected using the QFT, which does not directly imply or exclude the 
possibility that M. tuberculosis causes sarcoidosis.  The results of the QFT are 
reflected by the exposure level and amount of M. tuberculosis.  If M. tuberculosis 
causes sarcoidosis in a non-infectious fashion and in trace quantities, the release of 
interferon-gamma may be below the detection limit of the QFT.  Moreover, sarcoidosis 
is an immune disease that may not require continuous antigen exposure.  In contrast to 
our results, surprisingly, Drake et al. reported that one ESAT-6 peptide was recognized 
in 8 of 26 sarcoidosis patients (8).  They performed an ELISPOT assay with ESAT-6 
and their original KatG peptide, and found that these mycobacterial antigens induced 
T-cell responses in the blood of sarcoidosis patients.  Therefore, they suggested 
immunologic links between mycobacteria and sarcoidosis.  However, there are many 
differences between their study and the present study.  First, they targeted mainly 
African-Americans and more than half of their patients received certain 
immunosuppressive drugs.  Second, the ESAT-6 peptides in their ELISPOT assay were 
different from the seven types of proteins in our commercially available ELISA kit.  
Improving the sensitivity of the test and studies in various areas and races are required 
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to clarify the involvement of M. tuberculosis in the pathogenesis of sarcoidosis. 
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